Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing...

Full description

Bibliographic Details
Main Authors: Ha, Gavin (Author), Freeman, Samuel S. (Author), Choudhury, Atish D. (Author), Stover, Daniel G. (Author), Parsons, Heather A. (Author), Gydush, Gregory (Author), Reed, Sarah C. (Author), Rotem, Denisse (Author), Rhoades, Justin (Author), Livitz, Dimitri (Author), Rosebrock, Daniel (Author), Leshchiner, Ignaty (Author), Kim, Jaegil (Author), Stewart, Chip (Author), Rosenberg, Mara (Author), Francis, Joshua M. (Author), Zhang, Cheng-Zhong (Author), Cohen, Ofir (Author), Oh, Coyin (Author), Polak, Paz (Author), Lloyd, Max (Author), Mahmud, Sairah (Author), Helvie, Karla (Author), Merrill, Margaret S. (Author), Santiago, Rebecca A. (Author), O'Connor, Edward P. (Author), Jeong, Seong H. (Author), Kramkowski, Joseph F. (Author), Zhang, Zhenwei (Author), Polacek, Laura (Author), Lohr, Jens G. (Author), Schleicher, Molly (Author), Lipscomb, Emily (Author), Saltzman, Andrea (Author), Oliver, Nelly M. (Author), Marini, Lori (Author), Waks, Adrienne G. (Author), Harshman, Lauren C. (Author), Tolaney, Sara M. (Author), Van Allen, Eliezer M. (Author), Winer, Eric P. (Author), Lin, Nancy U. (Author), Nakabayashi, Mari (Author), Taplin, Mary-Ellen (Author), Johannessen, Cory M. (Author), Garraway, Levi A. (Author), Golub, Todd R. (Author), Boehm, Jesse S. (Author), Wagle, Nikhil (Author), Getz, Gad (Author), Meyerson, Matthew (Author), Adalsteinsson, Viktor A. (Contributor), Loginov, Denis (Contributor), Ding, Huiming (Contributor), Leeson, Rachel (Contributor), Barry, Rachel M (Contributor), Love, John C (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Nature Publishing Group, 2017-12-11T20:16:51Z.
Subjects:
Online Access:Get fulltext
LEADER 04316 am a22009133u 4500
001 112694
042 |a dc 
100 1 0 |a Ha, Gavin  |e author 
100 1 0 |a Massachusetts Institute of Technology. Department of Chemical Engineering  |e contributor 
100 1 0 |a Koch Institute for Integrative Cancer Research at MIT  |e contributor 
100 1 0 |a Adalsteinsson, Viktor A.  |e contributor 
100 1 0 |a Loginov, Denis  |e contributor 
100 1 0 |a Ding, Huiming  |e contributor 
100 1 0 |a Leeson, Rachel  |e contributor 
100 1 0 |a Barry, Rachel M  |e contributor 
100 1 0 |a Love, John C  |e contributor 
700 1 0 |a Freeman, Samuel S.  |e author 
700 1 0 |a Choudhury, Atish D.  |e author 
700 1 0 |a Stover, Daniel G.  |e author 
700 1 0 |a Parsons, Heather A.  |e author 
700 1 0 |a Gydush, Gregory  |e author 
700 1 0 |a Reed, Sarah C.  |e author 
700 1 0 |a Rotem, Denisse  |e author 
700 1 0 |a Rhoades, Justin  |e author 
700 1 0 |a Livitz, Dimitri  |e author 
700 1 0 |a Rosebrock, Daniel  |e author 
700 1 0 |a Leshchiner, Ignaty  |e author 
700 1 0 |a Kim, Jaegil  |e author 
700 1 0 |a Stewart, Chip  |e author 
700 1 0 |a Rosenberg, Mara  |e author 
700 1 0 |a Francis, Joshua M.  |e author 
700 1 0 |a Zhang, Cheng-Zhong  |e author 
700 1 0 |a Cohen, Ofir  |e author 
700 1 0 |a Oh, Coyin  |e author 
700 1 0 |a Polak, Paz  |e author 
700 1 0 |a Lloyd, Max  |e author 
700 1 0 |a Mahmud, Sairah  |e author 
700 1 0 |a Helvie, Karla  |e author 
700 1 0 |a Merrill, Margaret S.  |e author 
700 1 0 |a Santiago, Rebecca A.  |e author 
700 1 0 |a O'Connor, Edward P.  |e author 
700 1 0 |a Jeong, Seong H.  |e author 
700 1 0 |a Kramkowski, Joseph F.  |e author 
700 1 0 |a Zhang, Zhenwei  |e author 
700 1 0 |a Polacek, Laura  |e author 
700 1 0 |a Lohr, Jens G.  |e author 
700 1 0 |a Schleicher, Molly  |e author 
700 1 0 |a Lipscomb, Emily  |e author 
700 1 0 |a Saltzman, Andrea  |e author 
700 1 0 |a Oliver, Nelly M.  |e author 
700 1 0 |a Marini, Lori  |e author 
700 1 0 |a Waks, Adrienne G.  |e author 
700 1 0 |a Harshman, Lauren C.  |e author 
700 1 0 |a Tolaney, Sara M.  |e author 
700 1 0 |a Van Allen, Eliezer M.  |e author 
700 1 0 |a Winer, Eric P.  |e author 
700 1 0 |a Lin, Nancy U.  |e author 
700 1 0 |a Nakabayashi, Mari  |e author 
700 1 0 |a Taplin, Mary-Ellen  |e author 
700 1 0 |a Johannessen, Cory M.  |e author 
700 1 0 |a Garraway, Levi A.  |e author 
700 1 0 |a Golub, Todd R.  |e author 
700 1 0 |a Boehm, Jesse S.  |e author 
700 1 0 |a Wagle, Nikhil  |e author 
700 1 0 |a Getz, Gad  |e author 
700 1 0 |a Meyerson, Matthew  |e author 
700 1 0 |a Adalsteinsson, Viktor A.  |e author 
700 1 0 |a Loginov, Denis  |e author 
700 1 0 |a Ding, Huiming  |e author 
700 1 0 |a Leeson, Rachel  |e author 
700 1 0 |a Barry, Rachel M  |e author 
700 1 0 |a Love, John C  |e author 
245 0 0 |a Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors 
260 |b Nature Publishing Group,   |c 2017-12-11T20:16:51Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/112694 
520 |a Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing. 
520 |a American Association for Cancer Research (Award U2C-AACR-DT0712) 
655 7 |a Article 
773 |t Nature Communications